2021 Healthcare Research Review – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “2021 Healthcare Research Review” report has been added to ResearchAndMarkets.com’s offering. This Research Review is a collection of highlights from several healthcare market research reports that were published in 2019. This review was compiled with an intent of providing a sampling of the type of market information, guidance, and analysis, that have been … [Read more…]

Evonetix Appoints Colin McCracken as Chief Executive Officer

CAMBRIDGE, England–(BUSINESS WIRE)–EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the appointment of Colin McCracken as Chief Executive Officer with immediate effect. Colin’s appointment will support the next phase of the Company’s development and the commercialisation of its semiconductor-based DNA synthesis platform. Colin brings over 20 years’ experience … [Read more…]

Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer

Dr Leroy will oversee the pipeline of the company in immuno-oncology and will be responsible for advancing the GPCR programs to the clinic STRASBOURG, France & MONTREAL, Canada–(BUSINESS WIRE)–Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announced that it is … [Read more…]

Biotech Firm Tackling COVID-19 and M. bovis Announces Successful Development of Rapid, Accurate Johne’s Disease Assay

LOS ANGELES–(BUSINESS WIRE)–Auckland-based biotechnology company Pictor Limited has been developing an accurate, affordable multiplexed diagnostic test for Mycobacterium avium paratuberculosis (MAP) – also known as Johne’s disease, that could save the New Zealand dairy industry upwards of $80 million a year in lost production. “The PictArray™ MAP assay would be a positive addition to national … [Read more…]

Come Chill at Dexcom’s ‘No Pricks Parlour’ With Ed Gamble for Diabetes Awareness Week, Celebrating You!

This year’s Diabetes Awareness Week (13-19 June) is celebrating the triumphs and challenges for all people with diabetes. To celebrate the week, as well as the updated NICE (National Institute of Health and Care Excellence) guidelines, which will allow more people than ever before have access to modern diabetes management technology, Dexcom is hosting its … [Read more…]

Bryan Garnier & Co Initiates the Coverage of Median Technologies with a “Buy” Recommendation

SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News: Median Technologies (ALMDT) announces today the publication of an initiation report by Bryan Garnier & Co, a pan-European investment bank focusing on growth companies. In the initiation report published on June 10, 2022, Bryan Garnier & Co initiates the coverage of the stock with a buy recommendation and values the … [Read more…]

Analysis of Pooled Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials Reinforces Safety Profile in People with Thyroid Eye Disease (TED)

— Data presented at ENDO 2022 indicates low rates of hyperglycemic events were easily controlled, did not cause treatment disruption and were most often seen in patients with pre-existing diabetes — — A separate poster presentation examined response to TEPEZZA in patients who were mildly hypothyroid and found outcomes were consistent with those in the … [Read more…]

Orphagen Pharmaceuticals Presents Data on Downstream Targets of SF-1 Antagonist OR-449 at ENDO 2022

SAN DIEGO–(BUSINESS WIRE)–Orphagen Pharmaceuticals, an early-stage biopharmaceutical company focused on developing and commercializing novel therapies for cancer and other serious diseases with significant unmet need, today announced that additional data from its preclinical program to develop OR-449 for the treatment of adrenocortical cancer (ACC) was presented at the 104th Annual Meeting of the Endocrine Society … [Read more…]

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell therapy Total patient population achieved overall response rate (ORR) of 63 percent and complete response (CR) of 39 percent; CAR T-naïve patients achieved 69 percent ORR and 42 percent CR; patients previously … [Read more…]

Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress

– Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to be a one-time functional cure – – Safety profile generally consistent with myeloablative conditioning and autologous stem cell transplant – BOSTON & ZUG, Switzerland & … [Read more…]